AstraZeneca Lifted By Tagrisso Combo Lung Cancer Data
Shows Improvement Over Monotherapy
Data from the FLAURA2 trial suggest AstraZeneca could soon be able to expand use of Tagrisso in the first-line setting, widening the gap over Johnson & Johnson’s Rybrevant.
You may also be interested in...
Improvements in PFS compared to chemotherapy may help broaden Rybrevant’s indication in EGFR-mutated non-small cell lunger cancer. Investors await data from a head-to-head trial testing it versus AstraZeneca’s Tagrisso.
AstraZeneca’s Tagrisso could consolidate its place in EGFR-positive lung cancer, while Daiichi looks to go it alone with its own antibody-drug conjugate.
In this week's podcast edition of Five Must-Know Things: US FTC takes action on Amgen’s Horizon deal; Hassan and Jimenez share their CEO experiences; Novartis lays out Cosentyx plans; generally strong fiscal year for Japan’s pharma firms; and new Tagrisso data lift AstraZeneca.